---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-080562"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2026-07-06T11:00:40+00:00"
generated_at: "2026-07-06T11:05:10.503658+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Regeneron expects ~$127M IPR&D charge in Q2 2026, reducing EPS by ~$1.00

## Summary
- Pre-tax acquired IPR&D charge of ~$127M from collaboration and licensing up-front/opt-in payments.
- Charge expected to reduce both GAAP and non-GAAP diluted EPS by ~$1.00 in Q2 2026.
- Q2 2026 results not finalized; subject to financial statement closing procedures.
- Company does not forecast such IPR&D charges due to uncertainty of timing and magnitude.

## SEC filing metadata
- accession: 0001104659-26-080562
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2026-07-06T11:00:40+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000110465926080562/0001104659-26-080562-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000110465926080562/tm2619682d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-080562
- JSON: https://secwatch.observer/filing/0001104659-26-080562.json
- Plain text: https://secwatch.observer/filing/0001104659-26-080562.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.